Gene Therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. A gene can be delivered to a cell using a carrier known as a “vector.” The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.
This report contains market size and forecasts of Gene Therapy for CNS Disorders in Global, including the following market information:
Global Gene Therapy for CNS Disorders Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Gene Therapy for CNS Disorders market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Ex Vivo Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Gene Therapy for CNS Disorders include Gilead (Kite Pharma), Amgen (BioVex), Novartis, Roche (Spark Therapeutics) and Bluebird Bio, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Gene Therapy for CNS Disorders companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Gene Therapy for CNS Disorders Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Gene Therapy for CNS Disorders Market Segment Percentages, by Type, 2021 (%)
Ex Vivo
In Vivo
Global Gene Therapy for CNS Disorders Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Gene Therapy for CNS Disorders Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Gene Therapy for CNS Disorders Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Gene Therapy for CNS Disorders Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Gene Therapy for CNS Disorders revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Gene Therapy for CNS Disorders revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Gilead (Kite Pharma)
Amgen (BioVex)
Novartis
Roche (Spark Therapeutics)
Bluebird Bio